Skip to main content
TipRanks
Go Ultimate75% OFF

PharmaCielo (PCLOF) AI Stock Analysis

90 Followers
PCLOF

PharmaCielo

(Other OTC:PCLOF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthA roughly 42% TTM revenue rebound indicates improved commercial traction and renewed demand for the company’s cannabis-derived ingredients. If sustained, higher volume can provide operating leverage, support broader customer adoption, and create a stronger base for future profitability.
Negative Factors
Persistent UnprofitabilityPersistent EBIT and net losses show that the recent revenue and margin improvements have not yet scaled enough to cover the company’s operating cost base. Continued losses can consume capital, restrict reinvestment, and delay the point at which the business becomes self-sustaining.

PharmaCielo (PCLOF) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%200%250%300%PCLOF+29.63%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$7.02M
Dividend Yield
―
Average Volume (3M)
20.51K
Price to Earnings (P/E)
-2.4
Beta (1Y)
-1.90
Revenue Growth
1.65%
EPS Growth
57.28%
Country
US
Employees
268
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

PharmaCielo Business Overview & Revenue Model

Company Description

PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medici...

PharmaCielo Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PCLOF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:AVCNTSE:AVCN58NeutralCAD 12.09M-3.98-65.40%―-3.32%-34.15%
TSE:LABSTSE:LABS57NeutralCAD 27.77M-9.23-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:OILSTSE:OILS43NeutralCAD 3.40M-1.75-43.92%―-18.30%-397.37%
TSE:ATLETSE:ATLE42NeutralCAD 39.63M-0.76-2099.75%―-96.13%88.13%
TSE:INNOTSE:INNO41NeutralCAD 8.28M-6.18-19.37%―-19.20%42.54%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%PCLOFTSE:ATLETSE:LABSTSE:OILSTSE:AVCNTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PCLOF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PCLOFPharmacielo0.040.0152.17%
TSE:ATLEWillow Biosciences0.09-0.06-39.29%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-14.29%
TSE:OILSNextleaf Solutions 0.02-0.03-60.00%
TSE:AVCNAvicanna Inc0.09-0.16-64.80%
TSE:INNOInnocan Pharma Corporation1.84-13.55-88.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.